Business / Finance

RSS

AstraZeneca, HSCI collaborate to find new treatments for diabetes

AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

26 Mar 2015

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio.

26 Mar 2015

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.

26 Mar 2015

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.

25 Mar 2015

Pentax Medical announces new chief marketing officer and Americas region president

David Woods, the current president of PENTAX Medical of the Americas, has been appointed as the new global Chief Marketing Officer (CMO), effective April 1, 2015...

25 Mar 2015

Vermillion announces total revenue of $1.6 million for fourth quarter 2014

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter ended and full year ended December 31, 2014.

From Quest Diagnostics 25 Mar 2015

Sun Pharma closes Ranbaxy merger

Sun Pharmaceutical Industries Ltd., today, begins the integration of Ranbaxy's business following the successful closure of its merger.

25 Mar 2015

Omnicell receives notification from NASDAQ OMX Group for noncompliance with Nasdaq Listing Rule

As indicated in a Form 8-K filed with the SEC on March 20, 2015, Omnicell, Inc. received a written notification from the NASDAQ OMX Group, Inc. on March 18, 2015, indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing, due to the delay in filing its Annual Report on Form 10-K for the period ended December 31, 2014 beyond the extended filing due date of March 17, 2015.

From Omnicell, Inc. 25 Mar 2015

Beaumont Health joins UHC and Novation to increase cost savings, improve supply chain performance

UHC announced today that Beaumont Health has partnered with UHC and its supply contracting company, Novation, on a new two-year initiative designed to increase cost savings and supply chain performance improvement.

25 Mar 2015

Funding helps researchers to kiss MS goodbye

Murdoch University researchers have received funding to investigate the link between the Epstein-Barr virus infection, more commonly known as glandular fever or the ‘kissing disease’, and the debilitating disease Multiple Sclerosis (MS).

24 Mar 2015

Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

Confluence is a biopharmaceutical company focused on developing therapeutic treatments for Fragile X Syndrome and Autism Spectrum Disorders. AOP is an Austrian based company specializing in the development and marketing of medicines for rare and complex diseases.

24 Mar 2015

Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced operational, clinical and financial results for the year ended December 31, 2014.

24 Mar 2015

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013.

24 Mar 2015

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor.

24 Mar 2015

Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology.

24 Mar 2015

Affiliate of American Securities enters into definitive agreement to recapitalize Aspen Dental

American Securities LLC, Ares Management, L.P., and Leonard Green & Partners, L.P. today announced that an affiliate of American Securities has entered into a definitive agreement to recapitalize Aspen Dental Management Inc. in partnership with the management team and funds affiliated with Ares and Leonard Green. Terms of the transaction were not disclosed.

24 Mar 2015

Bruker’s new Wine and Honey screeners deliver easy, comprehensive cost efficient analysis

The inherent ease of use allows non-expert users to conduct analyses from measurement to final report in minutes and without chromatography.

23 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

OrthoSensor raises $19 million in Series C Preferred Stock financing

OrthoSensor, Inc., the leader in Sensor-Assisted Surgery, announced today that it has raised $19 million in a private placement of Series C Preferred Stock. Bridger Healthcare, Ltd. and The Tullis Growth Fund, L.P. participated in the round. The proceeds will be used to drive the commercialization of VERASENSE, OrthoSensor's leading product, and expand product development activities.

23 Mar 2015

Everyday Health announces acquisition of Cambridge BioMarketing Group

Everyday Health, Inc., a leading provider of digital health and wellness solutions, today acquired Cambridge BioMarketing Group, LLC, the leader in strategic launch and marketing solutions for orphan and rare disease products.

23 Mar 2015

Business / Finance

AstraZeneca, HSCI collaborate to find new treatments for diabetes

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Lycera achieves milestone in Merck research collaboration

Pentax Medical announces new chief marketing officer and Americas region president

Vermillion announces total revenue of $1.6 million for fourth quarter 2014

Sun Pharma closes Ranbaxy merger

Omnicell receives notification from NASDAQ OMX Group for noncompliance with Nasdaq Listing Rule

Beaumont Health joins UHC and Novation to increase cost savings, improve supply chain performance

Funding helps researchers to kiss MS goodbye

Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

GenVec reports record financial results for Q4 and fiscal year 2014

Rigontec raises €4.8 million in second closing of Series A financing round

Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

Affiliate of American Securities enters into definitive agreement to recapitalize Aspen Dental

Bruker’s new Wine and Honey screeners deliver easy, comprehensive cost efficient analysis

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

OrthoSensor raises $19 million in Series C Preferred Stock financing

Everyday Health announces acquisition of Cambridge BioMarketing Group

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News